Multiparameter MR Imaging in the 6-OPRI Variant of Inherited Prion Disease

REFERENCES

1. 1.↵
   1. Ledingham JGG,
   2. Warrell DA

   1. Collinge J

   . Prion diseases. In: Ledingham JGG, Warrell DA, eds. Concise Oxford Textbook of Medicine. New York: Oxford University Press, 2000;1307–11
2. 2.↵
   1. Collinge J,
   2. Rossor M

   . A new variant of prion disease. Lancet 1996;347:916–17

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Hill AF,
   2. Collinge J

   . Subclinical prion infection in humans and animals. Br Med Bull 2003;66:161–70

   Abstract/FREE Full Text
4. 4.↵
   1. Llewelyn CA,
   2. Hewitt PE,
   3. Knight RS,
   4. et al

   . Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417–21

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Wroe SJ,
   2. Pal S,
   3. Siddique D,
   4. et al

   . Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006;368:2061–67

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Mead S

   . Prion disease genetics. Eur J Hum Genet 2006;14:273–81

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Kaski DN,
   2. Pennington C,
   3. Beck J,
   4. et al

   . Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. Brain 2011;134:1829–38

   Abstract/FREE Full Text
8. 8.↵
   1. Mead S,
   2. Poulter M,
   3. Beck J,
   4. et al

   . Inherited prion disease with six octapeptide repeat insertional mutation–molecular analysis of phenotypic heterogeneity. Brain 2006;129:2297–317

   Abstract/FREE Full Text
9. 9.↵
   1. Alner K,
   2. Hyare H,
   3. Mead S,
   4. et al

   . Distinct neuropsychological profiles correspond to distribution of cortical thinning in inherited prion disease caused by insertional mutation. J Neurol Neurosurg Psychiatry 2012;83:109–14

   Abstract/FREE Full Text
10. 10.↵
    1. Fox NC,
    2. Freeborough PA,
    3. Mekkaoui KF,
    4. et al

    . Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease. BMJ 1997;315:856–57

    FREE Full Text
11. 11.↵
    1. Hyare H,
    2. Thornton J,
    3. Stevens J,
    4. et al

    . High-b-value diffusion MR imaging and basal nuclei apparent diffusion coefficient measurements in variant and sporadic Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol 2010;31:521–26

    Abstract/FREE Full Text
12. 12.↵
    1. Hyare H,
    2. Wroe S,
    3. Siddique D,
    4. et al

    . Brain-water diffusion coefficients reflect the severity of inherited prion disease. Neurology 2010;74:658–65

    CrossRef
13. 13.↵
    1. Siddique D,
    2. Hyare H,
    3. Wroe S,
    4. et al

    . Magnetization transfer ratio may be a surrogate of spongiform change in human prion diseases. Brain 2010;133:3058–68

    Abstract/FREE Full Text
14. 14.↵
    1. Lee H,
    2. Hoffman C,
    3. Kingsley PB,
    4. et al

    . Enhanced detection of diffusion reductions in Creutzfeldt-Jakob disease at a higher B factor. AJNR Am J Neuroradiol 2010;31:49–54

    Abstract/FREE Full Text
15. 15.↵
    1. Ashburner J,
    2. Friston KJ

    . Voxel-based morphometry–the methods. Neuroimage 2000;11:805–21

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Lee H,
    2. Rosenmann H,
    3. Chapman J,
    4. et al

    . Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain 2009;132:2680–87

    Abstract/FREE Full Text
17. 17.↵
    1. Lee H,
    2. Cohen OS,
    3. Rosenmann H,
    4. et al

    . Cerebral white matter disruption in Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol 2012;33:1945–50

    Abstract/FREE Full Text
18. 18.↵
    1. Cohen OS,
    2. Hoffmann C,
    3. Lee H,
    4. et al

    . MRI detection of the cerebellar syndrome in Creutzfeldt-Jacob disease. Cerebellum 2009;8:373–81

    CrossRefPubMed
19. 19.↵
    1. Collinge J,
    2. Gorham M,
    3. Hudson F,
    4. et al

    . Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334–44

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Folstein MF,
    2. Folstein SE,
    3. McHugh PR

    . “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Hughes CP,
    2. Berg L,
    3. Danziger WL,
    4. et al

    . A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–72

    Abstract/FREE Full Text
22. 22.
    1. Stejskal EO,
    2. Tanner JE

    . Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 1965;42:288–92

    CrossRefWeb of Science
23. 23.↵
    1. Barker GJ,
    2. Schreiber WG,
    3. Gass A,
    4. et al

    . A standardised method for measuring magnetisation transfer ratio on MR imagers from different manufacturers–the EuroMT sequence. MAGMA 2005;18:76–80

    CrossRefPubMed
24. 24.↵
    1. Barker GJ,
    2. Tofts PS,
    3. Gass A

    . An interleaved sequence for accurate and reproducible clinical measurement of magnetization transfer ratio. Magn Reson Imaging 1996;14:403–11

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Ashburner J,
    2. Friston KJ

    . Unified segmentation. Neuroimage 2005;26:839–51

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Ashburner J

    . A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95–113

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Mechelli A,
    2. Price CJ,
    3. Friston KJ,
    4. et al

    . Voxel-based morphometry of the human brain: methods and applications. Curr Med Imag Rev 2005;1:105–13

    CrossRef
28. 28.↵
    1. Ourselin S,
    2. Roche A,
    3. Subsol G,
    4. et al

    . Reconstructing a 3D structure from serial histological sections. Image Vis Comput 2001;19:25–31

    CrossRefWeb of Science
29. 29.↵
    1. Ourselin S,
    2. Stefanescu R,
    3. Pennec X

    . Robust registration of multi-modal images: Towards real-time clinical applications. In: Proceedings of Medical Image Computing and Computer-Assisted Intervention (MICCAI), Tokyo, Japan, September 25–28, 2002:140–47
30. 30.↵
    1. Ridgway GR,
    2. Omar R,
    3. Ourselin S,
    4. et al

    . Issues with threshold masking in voxel-based morphometry of atrophied brains. Neuroimage 2009;44:99–111

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Arata H,
    2. Takashima H,
    3. Hirano R,
    4. et al

    . Early clinical signs and imaging findings in Gerstmann-Sträussler-Scheinker syndrome (Pro102Leu). Neurology 2006;66:1672–78

    CrossRef
32. 32.↵
    1. Cordery RJ,
    2. Alner K,
    3. Cipolotti L,
    4. et al

    . The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease. J Neurol Neurosurg Psychiatry 2005;76:330–36

    Abstract/FREE Full Text
33. 33.↵
    1. Aguzzi A,
    2. Weissmann C

    . Prion diseases. Haemophilia 1998;4:619–27

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Middleton FA,
    2. Strick PL

    . Basal-ganglia ‘projections’ to the prefrontal cortex of the primate. Cereb Cortex 2002;12:926–35

    Abstract/FREE Full Text
35. 35.↵
    1. Haik S,
    2. Galanaud D,
    3. Linguraru MG,
    4. et al

    . In vivo detection of thalamic gliosis: a pathoradiologic demonstration in familial fatal insomnia. Arch Neurol 2008;65:545–49

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Oppenheim C,
    2. Brandel JP,
    3. Hauw JJ,
    4. et al

    . MRI and the second French case of vCJD. Lancet 2000;356:253–54

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Waldman AD,
    2. Jarman P,
    3. Merry RT

    . Rapid echoplanar diffusion imaging in a case of variant Creutzfeldt-Jakob disease; where speed is of the essence. Neuroradiology 2003;45:528–31

    CrossRefPubMed
38. 38.↵
    1. Kantarci K,
    2. Jack CR Jr.,
    3. Xu YC,
    4. et al

    . Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 2001;219:101–07

    PubMedWeb of Science
39. 39.↵
    1. Mascalchi M,
    2. Lolli F,
    3. Della Nave R,
    4. et al

    . Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004;232:867–73

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Kantarci K,
    2. Petersen C,
    3. Boeve BF,
    4. et al

    . DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2006;64:902–04
41. 41.↵
    1. Niendorf T,
    2. Dijkhuizen RM,
    3. Norris DG,
    4. et al

    . Biexponential diffusion attenuation in various states of brain tissue: implications for diffusion-weighted imaging. Magn Reson Med 1996;36:847–57

    PubMedWeb of Science
42. 42.↵
    1. Breithaupt M,
    2. Romero C,
    3. Kallenberg K,
    4. et al

    . Magnetic resonance imaging in E200K and V210I mutations of the prion protein gene. Alzheimer Dis Assoc Disord 2013;27:87–90

    CrossRefPubMed
43. 43.↵
    1. Casanova R,
    2. Srikanth R,
    3. Baer A,
    4. et al

    . Biological parametric mapping: A statistical toolbox for multimodality brain image analysis. Neuroimage 2007;34:137–43

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Oakes TR,
    2. Fox AS,
    3. Johnstone T,
    4. et al

    . Integrating VBM into the general linear model with voxelwise anatomical covariates. Neuroimage 2007;34:500–08

    CrossRefPubMedWeb of Science